, Volume 92, Issue 4, pp 470–472

Increased sensitivity of mice to tremorogenic agents following MPP+

  • G. C. Wagner
  • S. L. Walsh
Original Investigations


The behavioral effects following intrastriatal MPP+, the neurotoxic metabolite of MPTP, were evaluated in mice. Bilateral injections of 10 ίcro;g MPP+ to mice previously trained in the shuttle box paradigm produced a 66% decrease in striatal dopamine and significant deficits in all measures of conditioned avoidance responding. In addition, although these mice showed no deficits in baseline rotorod performance, challenge with the cholinergic agonist oxotremorine revealed that MPP+-treated mice exhibited an increased sensitivity to the disruptive effects of the drug at each dose and time point. Finally, MPP+-treated mice also exhibited an increase in tremor induced by 0.1 and 0.15 mg/kg oxotremorine. These observations are discussed in reference to idiopathic parkinsonism.

Key words

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine  1-Methyl-4-phenylpyridinium ion Dopamine Parkinson's disease Active avoidance Acetylcholine Tremor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ballard P, Tetrud J, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-Seven cases. Neurology 35:949–956Google Scholar
  2. Burns RS, Chiueh C, Markey S, Ebert M, Jacobowitz D, Kopin I (1983) A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550Google Scholar
  3. Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120 (2):574–578Google Scholar
  4. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz D, Kopin I (1983) I-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a parkinsonian syndrome causing agent in man and monkey, produces different effects in guinea pig and rat. The Pharmacologist 25:131Google Scholar
  5. Davis G, Williams A, Markey S, Ebert M, Caine E, Reichert C, Kopin I (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res 1:249–254Google Scholar
  6. Duvoisin R (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17:124–136Google Scholar
  7. Heikkila R, Hess A, Duvoisin R (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453Google Scholar
  8. Izumi K, Nomoto M, Koja T, Shimuzu T, Kishita C, Fukuda T (1984) Phenytoin potentiates methamphetamine induced behavior in mice. Pharmacol Biochem Behav 20:803–806Google Scholar
  9. Jarvis MF, Wagner GC (1985) Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine. Life Sci 36:249–254Google Scholar
  10. Lang AE (1984) Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: Controversies and new approaches. Can J Neurol Sci 11:210–220Google Scholar
  11. Langston JW (1985) MPTP Neurotoxicity: An overview and characterization of phases of toxicity. Life Sci 36:201–206Google Scholar
  12. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980PubMedGoogle Scholar
  13. Lenard LG, Beer B (1975) Relationship of brain levels of norepinephrine and dopamine to avoidance behavior in rats after intraventricular administration of 6-hydroxydopamine. Pharmacol Biochem Behav 3:895–899Google Scholar
  14. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: Effect of L-dopa. J Pharmacol Exp Ther 195:453–464Google Scholar
  15. Neill DB, Boggan WO, Grossman SP (1974) Impairment of avoidance performance by intrastriatal administration of 6-hydroxydopamine. Pharmacol Biochem Behav 2:97–103Google Scholar
  16. Seiden LS, Carlsson A (1963) Temporary and partial antagonism by L-dopa of reserpine induced suppression of a conditioned avoidance response. Psychopharmacologia 4:418–423Google Scholar
  17. Wagner GC, Gardener I, Tsigas DJ, Masters DB (1984) Tolerance following the repeated administration of phencyclidine: No relation to central catecholamine depletion. Drug Alcohol Depend 13:225–234Google Scholar
  18. Wagner GC, Jarvis MF, Rubin JG (1986) L-Dopa reverses the effects of MPP+ toxicity. Psychopharmacology 88:401–402Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • G. C. Wagner
    • 1
  • S. L. Walsh
    • 1
  1. 1.Department of PsychologyRutgers, The State UniversityNew BrunswickUSA

Personalised recommendations